Anti-hepatitis B virus drugs in clinical and preclinical development

Virologica Sinica

Volumn 23, Issue 2, 2008, Pages 137-145

  Wang, Gui Feng ^a   Shi, Li Ping ^a   Zuo, Jian Ping ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Anti HBV drugs; HBV; Immunomodulatory agents

Indexed keywords

16ALPHA BROMOEPIANDROSTERONE; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMPLIGEN; ANTIVIRUS AGENT; AT 130; BAY 38 7690; BAY 39 5493; BAY 41 4109; EHT 899; ENTECAVIR; HEPATITIS B VACCINE; HEPEX B; HORMONE; IMMUNOMODULATING AGENT; INTERFERON; LAMIVUDINE; LIVER PROTECTIVE AGENT; MOLIXAN; MONOCLONAL ANTIBODY; N [1 (ALPHA CHLOROBENZYLIDENE) 2 OXO 2 (1 PIPERIDINYL)ETHYL]BENZAMIDE; NEW DRUG; NOV 205; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; ORPHAN DRUG; PEGINTERFERON ALPHA2A; PYRIMIDINE DERIVATIVE; TELBIVUDINE; THYMOSIN ALPHA1; UNINDEXED DRUG; XTL 001;

ABSENCE OF SIDE EFFECTS; ANEMIA; ANOREXIA; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HUMAN; LEUKOPENIA; NEPHROTOXICITY; THROMBOCYTOPENIA; VIRUS RESISTANCE;

HEPATITIS B VIRUS;

EID: 49749136164     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-008-2945-8     Document Type: Article

References (41)

1. Announces of cubo pharmaceuticals: http://findarticles.com/p/articles/ mi_m0EIN/is_2005_August_9/ai_n1487-3142
2. Biron C A. 1998. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol, 10: 383-390.
3. Bowden S, Jackson K, Littlejohn M, et al. 2004. Quantification of HBV Covalently Closed Circular DNA from Liver Tissue by Real-Time PCR. In: Hepatitis B and D protocols (Lau J Y N, Hamatake R, eds.), Volume 1: Detection, Genotypes, and Characterization. Robert K. Hamatake, Johnson Y. N. Lau: HumanaPress, 41-51. ISBN: 1-59259-669-X Series: Methods in Molecular Medicine.
4. Cooksley W G, Piratvisuth T, Lee S D, et al. 2003. Peginterferon a-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B, J Viral Hepat, 10: 298-305.
5. De Clercq E. 2003. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev, 16: 569-596.
6. Delaney W E 4th, Edwards R, Colledge D, et al. 2002. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother, 46: 3057-3060.
7. Deres K, Schröder C H, Paessens A, et al. 2005. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science, 299: 893-896.
8. Digestive Disease Week, May 19-24, 2007, Washington DC. http://www.hivandhepatitis.com/2007icr/ddw/docs/052507b.html
9. Enzo therapeutics: http://www.enzobio.com/therapeutics/ product_pipeline.asp.
10. Hepatitis B fact sheet WHO/204 Geneva: World Health Organization. 2000. http:/www.who.int/infs/en/fact204. html (21 December 2005, date last accessed).
11. Jassim S A and Naji M A. 2003. Novel antiviral agents: A medicinal plant perspective. J Appl Microbiol, 95: 412-427.
12. Karayiannis P. 2003. Hepatitis B virus: Old, new and future approaches to antiviral treatment. J. Antimicrob. Chemother, 51: 761-785.
13. Keeffe E B, Marcellin P. 2007. New and emerging treatment of chronic hepatitis B. Clin Gastroenterol Hepatol. 5: 285-294.
14. King R W, Ladner S K, Miller T J, et al. 1998. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-) beta-L-2′, 3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother, 42: 3179-3186.
15. Kumar R, Agrawal B. 2004. Novel treatment options for hepatitis B virus infection. Curr Opin Investig Drugs, 5: 171-178.
16. Lai C L, Leung N, Teo E K, et al. 2005. Telbivudine Phase II Investigator Group. A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. Gastroenterology, 129: 528-536.
17. Lee H S, Chung Y H, Lee K, et al. 2006. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology, 43: 982-988.
18. Liang X F, Chen Y S, Wang X J, et al. 2005. A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old. Chin J Epidemiol, 26:655-660.
19. Liu J, Feitelson MA. 2004. Detection of Hepatitis B Virus X Antigen by Immunohistochemistry and Western Blotting. In: Hepatitis B and D protocols (Lau J Y N, Hamatake R, eds.), Volume 1: Detection, Genotypes, and Characterization. Robert K. Hamatake, Johnson Y. N. Lau: Humana-Press, 71-84. ISBN: 1-59259-669-X Series: Methods in Molecular Medicine.
20. Li Y F, Wang G F, He P L, et al. 2006. Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives. J Med Chem, 49: 4790-4794.
21. Lok A S F, McMahon B J. 2007. AASLD practice guidelines: Chronic hepatitis B. Hepatology, 45:507-539.
22. Nelson M. 2003. Telbivudine (L-dT) in phase III studies for chronic hepatitis B. Hepdart, December 14-18, Kauai, Hawai.
23. Nie Q H, Zhang J C. 2006. A meta-analysis of thymosin-monotherapy for chronic hepatitis B virus infection. Chin J Pract Int Med, 26: 382-386.
24. NO author listed. 2004. Mismatched double-stranded RNA: PolyI:polyC12U. Drugs R D, 5: 297-304.
25. Novartis Pharmaceuticals Corporation: http://daily med.nlm.nih.gov/ dailymed/drugInfo.cfm?id=3365
26. Novelos: http://www.novelos.com
27. Quan D J, Peters M G. 2004. Antiviral therapy: nucleotide and nucleoside analogs. Clin Liver Dis, 8: 371-385.
28. Romero M R, Efferth T, Serrano M A et al. 2005. Effect of artemisinin/ artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system. Antiviral Res, 68: 75-83.
29. Samuel C E. 2001. Antiviral actions of interferons. Clin Microbiol Rev, 14: 778-809.
30. Sorbera L A., Serradell N, Bolos J. 2007. Pradefovir Mesilate. Drugs Fut, 32: 137-143.
31. Source Hollis-Eden Pharmaceuticals, Inc. http://phx.corporate-ir.net/ phoenix.zhtml?c=113795&p=irol-newsar-ticle_print&ID=212253
32. Stoeckl L, Funk A, Kopitzki A, et al. 2006. Identification of a structural motif crucial for infectivity of hepatitis B viruses. Proc Natl Acad Sci USA, 103: 6730-6734.
33. Stray S J, Bourne C R, Punna S, et al. 2005. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci USA, 102: 8138-8143.
34. Sullivan S. 2006. Pradefovir a promising prodrug for hepatitis B. Meeting report. Inpharma Weekly, 1521:7-9, January 21.
35. van Bömmel F, Wünsche T, Mauss S, et al. 2004. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology, 40: 1421-1425.
36. van Bömmel F, Zöllner B, Sarrazin C, et al. 2006. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology, 44:318-325.
37. Wolters L M, Hansen B E, Niesters H G, et al. 2002. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganci-clovir, Eur J Gastroenterol Hepatol, 123: 1007-1011.
38. Ying C, Li Y, Leung C H, et al. 2007. Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc Natl Acad Sci USA, 104: 8526-8531.
39. ZADAXIN® (thymosin alpha 1): http://www.sciclone-international.com/ zadaxin.shtml
40. Zeuzem S, Welsch C, Herrmann E. 2003. Pharmacokinetics of Peginterferons. Semin Liver Dis, 23: 23-28.
41. Zoulim F. 2004. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res, 64:1-15.